Viatris Launches Tender Offer to Acquire Pacira BioSciences for $36.50 Per Share

Viatris's formal tender offer for Pacira BioSciences, commenced October 30, 2026, signals a significant shift in the company's specialty manufacturing footprint, one that plant operations and quality teams will need to begin mapping now. The all-cash offer of $36.50 per share values the transaction under a merger agreement signed October 8, 2026, with Pacira set to survive as a wholly owned Viatris subsidiary.

The structural mechanism is a short-form merger under Section 251(h) of the Delaware General Corporation Law, meaning no stockholder vote is required. Pacira's board has unanimously recommended that shareholders tender their shares, and the Schedule 14D-9 filed with the SEC on October 30 formalises that position. The offer window closes one minute after 11:59 p.m. Eastern Time on November 16, 2026, unless extended under the merger agreement's terms.

For QA directors and plant heads, the operational read centres on Pacira's liposomal drug delivery platform. Integrating a sterile, complex-formulation manufacturing base into Viatris's existing generics and specialty network will require early alignment on quality systems, particularly around process validation protocols, sterility assurance levels, and site-specific 21 CFR Part 211 compliance postures. Liposomal manufacturing carries distinct environmental monitoring and aseptic processing demands that differ materially from standard solid-dose or even conventional injectable operations.

Regulatory affairs leads should note that post-merger site consolidation or technology transfers involving Pacira's approved products, including any liposomal NDA-held assets, will trigger ICH Q10-aligned pharmaceutical quality system reviews and likely require prior approval supplements or CBE-30 filings depending on the scope of change. Early engagement with site master file documentation and product lifecycle management records will reduce lag between deal close and operational continuity.

Shares tendered may be withdrawn any time before the Expiration Date, and if not yet accepted for payment, withdrawal rights extend through December 29, 2026, the 60th day from offer commencement, providing a defined window before ownership formally transfers and integration planning moves from contingency to execution.

The November 16 expiration date sets the first measurable checkpoint against which integration readiness teams should benchmark their quality system gap assessments.

Source: Viatris newsroom via press release, October 30, 2026.